These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23110521)

  • 1. Diethylstilbestrol in castration-resistant prostate cancer.
    Sartor O
    BJU Int; 2012 Dec; 110(11 Pt B):E736. PubMed ID: 23110521
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of castration and stilboestrol on prostatic tumours in mice.
    HORNING ES
    Br J Cancer; 1949 Jun; 3(2):211-30. PubMed ID: 18132112
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of castration and di-ethyl stilboestrol in a patient with myelophthisic anemia secondary to carcinoma of the prostate.
    COMMONS RR; STRAUSS MB
    J Clin Invest; 1947 Nov; 26(6):1178. PubMed ID: 20272558
    [No Abstract]   [Full Text] [Related]  

  • 4. Bone changes and variations in skeletal metastases due to diethylstilbestrol and orchiectomy during treatment of cancer of the prostate.
    WATTENBERG CA
    J Urol; 1947 Nov; 58(5):378-83. PubMed ID: 20270530
    [No Abstract]   [Full Text] [Related]  

  • 5. Myelophthisic anemia the presenting manifestation of prostatic carcinoma with skeletal metastases; the effect of castration and stilbestrol.
    COMMONS RR; STRAUSS MB
    Am J Med Sci; 1948 May; 215(5):525-9. PubMed ID: 18101771
    [No Abstract]   [Full Text] [Related]  

  • 6. Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma.
    Jordan WP; Blackard CE; Byar DP
    South Med J; 1977 Dec; 70(12):1411-3. PubMed ID: 594790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carcinoma of prostate. Increased mortality and cardio-vascular complications associated with oestrogen therapy as compared with orchiectomy.
    Gardner AM; Setakis N
    Bristol Med Chir J; 1983 Jul; 98(367):117-9. PubMed ID: 6616292
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Prout GR
    Surg Forum; 1970; 21():540-1. PubMed ID: 5535268
    [No Abstract]   [Full Text] [Related]  

  • 9. Castration-resistant prostate cancer: adaptation or clonal selection? Insight from the EORTC 30891 trial.
    Tombal B
    Eur Urol; 2014 Nov; 66(5):839-40. PubMed ID: 24341957
    [No Abstract]   [Full Text] [Related]  

  • 10. Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business?
    Sonpavde G; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):574-575. PubMed ID: 26497920
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-58.
    Pitts WR
    Eur Urol; 2007 Mar; 51(3):864. PubMed ID: 16860461
    [No Abstract]   [Full Text] [Related]  

  • 12. Denosumab in castration-resistant prostate cancer.
    Kyrgidis A; Tzellos TG
    Lancet; 2012 May; 379(9828):e50; author reply e50-1. PubMed ID: 22579323
    [No Abstract]   [Full Text] [Related]  

  • 13. The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in patients with carcinoma of the prostate.
    Mackler MA; Liberti JP; Smith MJ; Koontz WW; Prout GR
    Invest Urol; 1972 Mar; 9(5):423-5. PubMed ID: 5016026
    [No Abstract]   [Full Text] [Related]  

  • 14. Prostate cancer: Bicalutamide dose increase in castration-resistant disease.
    Labrie F
    Nat Rev Urol; 2015 Mar; 12(3):132-3. PubMed ID: 25487048
    [No Abstract]   [Full Text] [Related]  

  • 15. A NEW PITUITARY-INHIBITING COMPOUND IN THE TREATMENT OF PROSTATIC CANCER.
    NYLANDER G; TERNER N
    Urol Int; 1964; 17():129-45. PubMed ID: 14168016
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on extragonadal androgen: hormonal changes of the prostatic cancer patients on antiandrogenic therapy after orchiectomy.
    Fukuda Y
    Kobe J Med Sci; 1968 Mar; 14(1):1-23. PubMed ID: 5674440
    [No Abstract]   [Full Text] [Related]  

  • 17. Orchiectomy has fewer adverse effects than chemical castration for metastatic prostate cancer.
    Wise J
    BMJ; 2015 Dec; 351():h6966. PubMed ID: 26705347
    [No Abstract]   [Full Text] [Related]  

  • 18. [Castration in the treatment of locally advanced or metastatic prostate cancer].
    Mongiat-Artus P
    Rev Prat; 2013 Apr; 63(4):509-10. PubMed ID: 23682480
    [No Abstract]   [Full Text] [Related]  

  • 19. Carcinoma of the prostate gland, and benefits of diethylstilbestrol or orchiectomy.
    WATTENBERG CA
    Mo Med; 1945 Aug; 42():482-5. PubMed ID: 21007328
    [No Abstract]   [Full Text] [Related]  

  • 20. Castration-resistant prostate cancer: targeted therapies.
    Leo S; Accettura C; Lorusso V
    Chemotherapy; 2011; 57(2):115-27. PubMed ID: 21430379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.